MAIA...........
Did you get a chance to come back to any of these
2014 ASCO Gastrointestinal Cancers Symposium abstracts???
I thought maybe
GrouseMan would dig the technical data
I have accessed a number of them regarding
molecular profiling,
molecular sub-typing and
bio-markers & their correlation to
Colorectal Cancer disease survival and
therapeutic implications. It has gone way past
KRAS, BRAF, NRAS and
EGFR Targeted therapiesI have particular interest in these as they relate to
PDL1/
Immunotherapy Drugs..........and whether they may work on my hubby with his particular genetic profiling.
Our Monday meeting regarding the
Ipilimumab and
Nivolumab Clinical trial may bring up the
Microsatellite Status (MSS and MSI) and
PDL1 status according to these......
Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to Microsatellite instability status.
Conclusions: Consideration of
immune checkpoint therapies for
colorectal cancer needs to consider the presence of PD-1 lymphocytes and cancer cell specific
PD-L1 expression.
PD-1+ IEL and
PD-L1+ cancer cells are more frequent in
MSI-H than in
MSS colorectal cancers, which are rare in general CRC population.
Immune checkpoints expression in MSI versus MSS colorectal cancers and their potential therapeutic implications.Conclusions: The genetic origin of CRC dictates the nature and intensity of inflammation. A strong IFNg -driven inflammatory response in
MSI CRC patients triggered the expression of
PD-L1 and
IDO-1 which could be
targeted to enhance clinical benefit and be predictive of response to immune checkpoint inhibitors.
Molecular profiling of 6,892 colorectal cancer patients to identify potential treatment options.Conclusions: Molecular profiling (MP) of 6,892 CRCs identified significant differences among tumors with
BRAF/KRAS-Mutant (MT) and metastases, prompting unexpected treatment options. Agents uncommonly used in CRC metastases such as temozolomide are suggested, and etoposide or taxanes are suggested for brain or ovarian mets, respectively. Targeted therapies could be considered for KRAS or BRAF mutated tumors based on actionable targets revealed by
Molecular ProfilingCHEERS!
Wife of Mike,
Vicki